Gan & Lee Pharmaceuticals. (SHA:603087)
China · Delayed Price · Currency is CNY 69.20
+2.86 (4.31%)
Sep 14, 2026, 3:00 PM CST
SHA:603087 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2,524 | 2,088 | 902.78 | 2,443 | 2,890 | 3,306 |
Short-Term Investments | - | - | - | - | 201.36 | 276.44 |
Trading Asset Securities | 996.42 | 1,401 | 1,500 | 2,410 | 1,636 | 1,624 |
Cash & Short-Term Investments | 3,520 | 3,489 | 2,403 | 4,853 | 4,728 | 5,206 |
Cash Growth | 57.34% | 45.20% | -50.48% | 2.66% | -9.20% | 14.24% |
Accounts Receivable | 785.83 | 599.87 | 246.72 | 383.74 | 189.57 | 934.66 |
Other Receivables | 5.51 | -0.55 | -1.12 | 1.63 | 0.99 | 0.16 |
Receivables | 791.34 | 599.32 | 245.6 | 385.37 | 190.55 | 934.82 |
Inventory | 1,056 | 1,009 | 1,053 | 860.51 | 648.65 | 651.33 |
Other Current Assets | 528.78 | 386.63 | 89.07 | 76.73 | 97.36 | 77.95 |
Total Current Assets | 5,896 | 5,484 | 3,791 | 6,176 | 5,664 | 6,870 |
Property, Plant & Equipment | 3,505 | 3,577 | 3,882 | 3,886 | 3,661 | 2,595 |
Long-Term Investments | 384.18 | 451.59 | 497.03 | 304.66 | 30 | 201.36 |
Other Intangible Assets | 617.92 | 265.11 | 273.06 | 278.08 | 293.48 | 295.99 |
Long-Term Deferred Tax Assets | 196.88 | 213.67 | 206.94 | 168.95 | 138.25 | 30.8 |
Long-Term Deferred Charges | 1,662 | 1,611 | 924.91 | 821.97 | 743.19 | 588.87 |
Other Long-Term Assets | 499.9 | 1,024 | 2,468 | 79.99 | 76.51 | 270.33 |
Total Assets | 12,762 | 12,627 | 12,043 | 11,715 | 10,607 | 10,853 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 201.68 | 126.21 | 115.61 | 94.82 | 36.52 | 26.15 |
Accrued Expenses | 148.63 | 287.07 | 183.44 | 192.54 | 190 | 173.04 |
Current Portion of Leases | - | 1.2 | 1.33 | 2.18 | 5.69 | 5.07 |
Current Income Taxes Payable | 54.82 | 14.53 | 1.49 | 1.42 | 1.35 | 106.32 |
Current Unearned Revenue | 12.4 | 67.88 | 63.25 | 52.99 | 68.13 | 36.56 |
Other Current Liabilities | 427.41 | 318.89 | 436 | 429.49 | 511.36 | 138.39 |
Total Current Liabilities | 853.37 | 815.79 | 801.13 | 773.45 | 813.04 | 485.53 |
Long-Term Leases | 2.25 | 2.54 | 3.31 | 5.45 | 8.33 | 12.17 |
Long-Term Unearned Revenue | 173.79 | 170.75 | 168.92 | 179.63 | 187.63 | 141.98 |
Long-Term Deferred Tax Liabilities | 20.61 | - | 12.11 | - | - | 36.15 |
Other Long-Term Liabilities | 2.68 | 9.5 | 2.97 | 14 | 12.27 | 10.2 |
Total Liabilities | 1,053 | 998.57 | 988.45 | 972.52 | 1,021 | 686.02 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 597.3 | 597.3 | 601.07 | 594.16 | 565.65 | 561.54 |
Additional Paid-In Capital | 3,545 | 3,534 | 3,591 | 3,351 | 2,563 | 2,476 |
Retained Earnings | 7,619 | 7,606 | 7,059 | 6,865 | 6,525 | 7,133 |
Treasury Stock | -52.97 | -111.17 | -200.85 | -71.36 | -71.36 | - |
Comprehensive Income & Other | 1.55 | 3.06 | 4.04 | 3.82 | 3.44 | -3.44 |
Total Common Equity | 11,709 | 11,628 | 11,054 | 10,743 | 9,586 | 10,167 |
Minority Interest | - | - | - | 0 | -0.16 | -0.16 |
Shareholders' Equity | 11,709 | 11,628 | 11,054 | 10,743 | 9,586 | 10,167 |
Total Liabilities & Equity | 12,762 | 12,627 | 12,043 | 11,715 | 10,607 | 10,853 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 10.68 | 3.74 | 4.64 | 7.62 | 14.01 | 17.24 |
Net Cash (Debt) | 3,509 | 3,486 | 2,399 | 4,846 | 4,714 | 5,189 |
Net Cash Growth | 57.14% | 45.32% | -50.50% | 2.80% | -9.16% | 13.86% |
Net Cash Per Share | 5.92 | 5.88 | 4.06 | 8.55 | 8.37 | 9.25 |
Filing Date Shares Outstanding | 600.75 | 591.12 | 598.96 | 590.05 | 561.54 | 561.54 |
Total Common Shares Outstanding | 600.75 | 591.12 | 598.96 | 590.05 | 561.54 | 561.54 |
Working Capital | 5,043 | 4,668 | 2,990 | 5,402 | 4,851 | 6,385 |
Book Value Per Share | 19.49 | 19.67 | 18.46 | 18.21 | 17.07 | 18.11 |
Tangible Book Value | 11,091 | 11,363 | 10,781 | 10,464 | 9,292 | 9,871 |
Tangible Book Value Per Share | 18.46 | 19.22 | 18.00 | 17.73 | 16.55 | 17.58 |
Buildings | - | 2,173 | 2,137 | 1,344 | 1,165 | 1,046 |
Machinery | - | 2,286 | 1,601 | 1,443 | 1,237 | 1,263 |
Construction In Progress | - | 393.47 | 1,262 | 2,007 | 2,003 | 874.91 |